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Case Presentation
In 1984 the patient, a 56-year-old white man,
developed intractable low back pain and pain
in his wrists without evidence of joint inﬂam-
mation. He had been a self-employed house
painter (50% interior work and 50% exterior)
for 36 years. During the course of his work,
he had removed paint by scraping, sanding,
and heat treatment with an electric iron
device. He wore a paper mask, but only spo-
radically, and never wore more sophisticated
respiratory protection devices. He commonly
smoked cigarettes (with a daily habit averag-
ing 1 pack/day) and ate at work without ﬁrst
washing his hands. After several months of
evaluations by an internist, rheumatologist,
and orthopedist and a number of unrevealing
diagnostic tests (including serologic tests and
back X-rays), a neurosurgeon ordered a blood
lead test. He was found to have a blood lead
level of 122 µg/dL and was hospitalized and
chelated by his primary care physician with
intravenous ethytenadiamine tetraacetic acid
(EDTA), which led to marked improvemet of
his symptoms. Despite warnings regarding
the risk of recurrent lead exposure and toxic-
ity, the patient returned to work as usual and
subsequently had three more cycles of symp-
tomatic lead toxicity requiring hospitalization
and chelation in 1986 (blood lead of 95
µ/dL), 1988 (blood lead of 106 µg/dL), and
August 1989 (blood lead of 95 µg/dL). In
April 1989, he developed hypertension,
which was controlled with enalapril.
Immediately after his last chelation, the
patient retired from house painting. He had
complained of mild short-term memory loss
and was referred to an occupational/environ-
mental medicine specialist. An outpatient
physical exam in late August 1989 revealed
no evidence of a “lead line” on his gums,
anemia, peripheral neuropathy, postural
imbalance, or other abnormality. An abbre-
viated mental status exam was within normal
limits. The patient’s postchelation blood
lead and zinc protoporphyrin levels were 81
µg/dL and 125 µg/dL, respectively, and
bone lead levels measured by a K-x-ray ﬂuo-
rescence (KXRF) instrument revealed tibia
(cortical) and patella (trabecular) bone lead
levels of 210 and 660 µg/g bone mineral,
respectively. His hemoglobin, hematocrit,
serum creatine, blood urea nitrogen, and
serum uric acid concentrations were within
normal limits (13.9 g/dL, 42.5%, 1.2
mg/dL, 25 mg/dL, and 5.5 mg/dL, respec-
tively). A urinalysis was normal.
Over the next 9 years, the patient’s lead
levels in trabecular bone and blood steadily
declined, whereas his cortical bone lead level
remained constant (Figure 1). In 1995, the
patient’s blood pressure, which had ranged
from 120 to 140 mmHg systolic and from
78 to 92 mmHg diastolic since beginning
antihypertensive therapy, became difﬁcult to
control. At this time systolics and diastolics
ranged from 140 to 190 mmHg and 84 to
104 mmHg, respectively, despite progres-
sively increasing dosages and types of med-
ications, including the addition of a
diuretic, nifedipine, and clonidine. His
body weight increased, but only about 5%
(from 160 to 168 lbs), and he remained
within 10% of his ideal body weight. The
patient’s blood counts, serum electrolytes,
and serum calcium remained in the normal
range, but his serum creatinine increased to
1.7 mg/dL. A urine analysis remained nor-
mal; a 24-hr urine collection revealed no
evidence of proteinuria, and his creatinine
clearance rate was 48 mL/min. Renal ultra-
sound revealed right and left kidneys of
10.1 and 10.5 cm in length, with some
thinning of the renal cortex, but there was
no evidence of hydronephrosis or other
abnormality.
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In 1984, a 56-year-old house painter developed intractable pain in his back and other joints. After
several unrevealing medical work-ups, he was found to have a high blood lead level (122 µg/dL);
he has a history of scraping and sanding lead paint without adequate protective measures. The
patient was hospitalized and chelated with EDTA four times over the next 5 years; each time he
felt better at the end of his treatment, but he returned to largely the same working conditions. He
developed hypertension in April 1989, underwent a final chelation, and retired. He was subse-
quently followed on a regular basis with repeated measurement of lead levels in blood and bone
(using a K-x-ray ﬂuorescence instrument) as well as clinical parameters. In 1995 his blood pres-
sure became difﬁcult to control despite a sequential increase in his antihypertensive medication
dosages and the addition of new medications. In 1997 he began calcium supplementation and a
high-calcium diet; his blood pressure declined markedly, allowing him to taper off of two of his
four antihypertensive medications. This case demonstrates an occupational activity (construction)
that has now become the dominant source of lead exposure for U.S. adults, the importance of a
good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic
lead toxicity, and the importance of preventing further exposure and using proper methods to
treat acute toxicity. It also highlights a current major etiologic question, that is, whether and to
what degree lead exposure contributes to the development of hypertension, and raises the issue of
whether lead-induced hypertension constitutes a subset of hypertension that is especially
amenable to therapy with dietary calcium. Key words: blood pressure, dietary calcium, hypertension,
K-x-ray ﬂuorescence, lead. Environ Health Perspect 109:95–99 (2001). [Online 21 December 2000]
http://ehpnet1.niehs.nih.gov/docs/2001/109p95-99hu/abstract.html
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sure remained high (systolic 160–180
mmHg; diastolic 90–110 mmHg) despite
his medication regimen. He was started on
calcium supplements (500 mg/day) and a
high-calcium diet (cheese, yogurt, and low-
fat milk). When next measured 4 weeks
later, his blood pressure had fallen (systolic
110–130 mmHg; diastolic 80–90 mmHg);
it remained in the normal range after
enalapril and clonidine were tapered and dis-
continued, and was still in the normal range
at his last visit in May 1998. The patient’s
serum creatinine, however, had risen to
1.9–2.0 mg/dL (Figure 1). An iodothalamate
study revealed a mean glomerular filtration
rate of 47.9 mL/min/1.73 m2 body surface
area (about 50% of normal renal function for
a man of his age). A kidney biopsy was
deferred on the patient’s wishes.
Discussion
This case evinces many of the major clinical
and public health issues surrounding acute
and chronic adult lead toxicity, including cur-
rent sources of exposure, diagnosis, treatment
of acute toxicity, the long life of an accumu-
lated lead burden, chronic toxicity, and treat-
ment strategies for chronic toxicity. The use
of lead paint in residences poses an enormous
risk to construction workers who remove it as
well as to the children who ingest lead paint
chips and lead-contaminated house dust. The
presence of lead paint in U.S. housing is per-
vasive: the majority of houses built before
1978 (estimated at 42–47 million houses)
have lead-based paint both inside and outside
(1). Lead paint typically contains around 50%
lead by weight. Scraping and, in particular,
sanding lead paint creates a ﬁne lead dust that
can be easily inhaled (Figure 2). Once
inhaled, absorption is efﬁcient, particularly if
the particles are small. Heating lead paint and
smoking contaminated cigarettes generate
lead fumes (ﬁne particles generated by burn-
ing), which are especially well absorbed by the
lungs. Hand-to-mouth activity (e.g., eating
and smoking without prior hand washing)
with subsequent ingestion and gastrointestinal
absorption is also a major source of lead expo-
sure in this setting.
Lead paint was used not only in resi-
dences but also in commercial buildings and
other structures such as bridges. Individuals
who remove exterior lead paint by sandblast-
ing or who use oxyacetylene torches to cut
through lead paint-coated steel are at partic-
ularly high risk of lead poisoning (2,3). [The
use of paint containing small amounts of
lead (< 0.25%) is still allowed on exterior
steel structures.] Thus, any construction
work involving older buildings and structures
carries a risk of lead exposure (4). In
Massachusetts, one of the 27 states that cur-
rently maintain central registries of blood
lead tests and report surveillance data to the
National Institute for Occupational Safety
and Health Adult Blood Lead Epidemiology
and Surveillance Program (5), construction
workers accounted for 63% of 381 individu-
als identified with blood lead levels of 40
µg/dL or higher (6).
In general, construction work is regulated
under the Occupational Health and Safety
Administration (OSHA) construction lead
standard (7) that took effect in 1993. Some
states have additional standards that apply
speciﬁcally to the painting and deleading of
residences [e.g., “Deleading” (8), passed in
Massachusetts in 1988)]. Such regulations
require, for example, the wearing of special
respirators and clothing (a paper mask is inad-
equate), “wet scraping” (to decrease dust),
chemical treatments (as opposed to sanding),
special environmental barriers, the prohibi-
tion of smoking and eating at work, and
regular blood lead tests. Unfortunately,
enforcement is difﬁcult and does nothing to
prevent lead exposure generated by enterpris-
ing home owners who expose themselves and
their children when they undertake renova-
tions themselves (9,10).
Presentation, diagnosis, and treatment
of acute lead toxicity. The diagnosis of acute
lead toxicity simply requires taking a blood
lead test, a test that is now performed in lab-
oratories throughout the United States that
participate in stringent quality control/qual-
ity assurance protocols. The mean blood
lead level for adults in the 50–69-year age
group of the general U.S. population is now
around 4.0 µg/dL (11), with only 7 and
0.3% of values exceeding 10 and 25 µg/dL,
respectively. Levels exceeding 10 µg/dL sug-
gest the possibility of an ongoing source of
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Figure 1. Serial measurements of bone lead levels (µg Pb/g bone mineral) in trabecular (patella) and corti-
cal (tibia) bone, serum creatinine levels (mg/dL), and blood lead levels (µg/dL) in the patient. 
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Patella
Tibialead exposure, and most occupational regula-
tions now require blood lead levels to remain
below 40 µg/dL.
The problem with diagnosing acute lead
toxicity is not the test, but suspecting the
diagnosis (which makes it possible to run
tests necessary for an accurate diagnosis). The
manifestations of lead toxicity are subtle and
vary from individual to individual. Joint
pains, muscle aches, abdominal pain (“lead
colic”), headache, fatigue, irritability, depres-
sion, constipation, decreased libido, anorexia,
and other symptoms have all been described
in various combinations (12). Although a
“lead line,” a zone of deep pigmentation on
the gums along the gum–tooth border, and
motor neuropathies of the median and per-
oneal nerves can sometimes be seen on a
physical exam with blood lead levels exceed-
ing 80 µg/dL, they are neither sensitive nor
specific findings. Similarly, basophilic stip-
pling on a blood smear with or without ane-
mia can be seen on a routine laboratory
evaluation, but it is neither a sensitive nor a
specific finding. Suspecting the diagnosis
rests entirely on taking a good history that
allows the review of possible environmental
and occupational activities of relevance and
knowing that such activities carry the risk of
signiﬁcant lead exposure.
The treatment of acute lead toxicity with
intravenous EDTA, as used in this case,
remains the standard method for managing
lead toxicity; the addition of British anti-
Lewisite (BAL or dimercaprol) is recom-
mended at very high levels of exposure (i.e.,
blood lead levels >100 µg/dL) to avoid exac-
erbation of central nervous system toxicity
that may result from transient redistribution
of lead to the brain during EDTA chelation.
Oral chelation can also be accomplished with
dimercaptosuccinic acid (DMSA or suc-
cimer), which is approved by the U.S. Food
and Drug Administration for treatment of
lead poisoning in children but is also effective
in adults (13); 500 mg should be given twice
daily for 2 weeks, with blood lead levels and
renal and liver function parameters monitored
before and after treatment. Clinicians should
be aware that blood lead levels (and symp-
toms) may rebound within a few days of ﬁn-
ishing chelation, at which point another
round of chelation may be advisable. 
It is especially important to note that
chelation should never be undertaken unless
exposure has been definitely terminated
because chelation can result in enhanced
absorption of lead and worsening of toxicity
if exposure continues. 
Lead, hypertension, and renal insuffi-
ciency. The patient developed hypertension
in 1989. In the absence of evidence indicat-
ing that he had one of the secondary forms
of hypertension, he can be considered to
have developed “essential hypertension.” 
Did lead exposure cause the patient’s
hypertension? The mechanisms responsible
for essential hypertension remain obscure,
probably because of the variety of systems
that are involved in the regulation of arterial
pressure and the complexity of their interrela-
tions (14). Essential hypertension probably
represents a heterogeneous set of disorders
that may involve the interplay of a number of
factors linked to essential hypertension,
including genetic and environmental factors,
salt sensitivity, endocrinologic factors mani-
fest in variations in plasma renin activity, cell
membrane defect, and insulin resistance (14). 
The evidence favoring lead exposure as a
signiﬁcant risk factor for the development of
hypertension is based on experimental animal
studies in several species [for example, recent
studies in rats (15,16)] as well as epidemio-
logic studies of blood pressure in relation to
blood lead levels [for example, see reviews by
Hertz-Picciotto and Croft (17) and Schwartz
(18)]. With regard to the epidemiologic evi-
dence, the blood lead–blood pressure rela-
tionship has been somewhat inconsistent
(19). Most, but not all, of the studies have
demonstrated that blood lead increases from
10 to 25 µg/dL are associated with systolic
and diastolic blood pressure increases of
1.4–8 mmHg and 1.2–4 mmHg, respectively
(17). However, in the studies demonstrating
such effects, several of the relationships do
not persist after adjusting for potential con-
founders. A potential reason for the lack of
robustness of the blood lead–blood pressure
relationship in some of these studies is that
most have relied on blood lead levels to
reﬂect lead exposure. With a mean half-life of
only around 30 days (20), blood lead levels
mostly reflect recent exposure, whereas the
most important predictor of chronic toxicity
is arguably cumulative lead exposure. Because
> 95% of lead in adults is stored in the skele-
ton (21,22), where lead has a half-life of years
to decades, bone lead is superior to blood
lead as a biological marker of cumulative lead
exposure.
Recently, my laboratory used a KXRF
instrument, which was developed to make
rapid noninvasive in vivo measurements of
lead in bone, to study 590 middle-aged to
elderly men participating in an epidemio-
logic study of chronic disease (23). Blood
lead levels were also measured. We found
that family history of hypertension (a proxy
of genetic influences), body mass index (an
indicator of obesity), and levels of lead in
cortical bone (but not blood) were the major
predictors of the development of hyperten-
sion. Bone lead was also found to predict
development of hypertension in a prospec-
tive study of these men (24), and a similar
relationship was found among middle-aged
female nurses (25). 
In contrast, Schwartz and Stewart (26)
recently found that blood lead levels, but not
bone lead levels, were correlated with blood
pressure. All of these studies are recent and
should be followed up by additional research.
In the case of the patient described in this
paper, the ranges of lead levels from his tibia
(cortical bone) and patella (trabecular bone)
are approximately 10 times the levels seen in
community-exposed men of his age (27); thus,
if bone lead were a major predictor of hyper-
tension, his risk would be extremely high. 
The patient’s bone lead levels over time
also demonstrate the long half-life of lead in
cortical bone (the tibia) in contrast to trabec-
ular bone (the patella). Since his retirement
in 1989, trabecular bone probably constitutes
the major continuing source of blood lead in
the patient through resorption and mobiliza-
tion (28). In the studies demonstrating that
bone lead level is a risk factor for hyperten-
sion (23–25), the relationship was stronger
for cortical bone lead in men and stronger for
trabecular bone lead in women. This may
reﬂect sex differences in bone turnover rates
and, consequently, the compartment of lead
storage that is critical to toxicity.
It is also notable that the patient described
in this paper developed early renal insuffi-
ciency, an outcome for which chronic lead
toxicity carries a high risk (29). It is likely that
his renal insufficiencey contributed toward
the difﬁculty in controlling hypertension that
began in 1995. However, it is unclear to what
extent renal insufficiency may have con-
tributed to his initial development of hyper-
tension. The patient’s normal serum
creatinine during the ﬁrst few years of hyper-
tension argues against kidney disease as a sec-
ondary cause of his hypertension, but it is
possible that subclinical alterations of kidney
function can increase blood pressure without
apparent changes in serum creatinine. It is
also possible that lead may contribute to sub-
clinical alterations of kidney function, a phe-
nomenon that has been suggested by a
number of epidemiologic studies (30,31). 
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Figure 2. A worker removing lead paint and wear-
ing appropriate personal protective gear [includ-
ing a Tyvac suit and a purified air-powered
respirator with high-efficiency particulate air
(HEPA) ﬁltration].
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aLead, calcium, and hypertension. Of spe-
cial interest is the apparent response of the
patient’s hypertension to increased dietary
calcium. Over the past 20 years, a plethora
of epidemiologic and clinical studies have
suggested that dietary calcium has an impor-
tant inﬂuence on blood pressure regulation,
with low levels carrying a risk of elevated
blood pressure (32). Also, the uptake and
metabolism of lead may be modiﬁed by cal-
cium status. Blood lead levels and dietary
calcium intake have been observed to be
inversely correlated in children as well as in
adults (33–36). In experimental models, a
low-calcium diet increased the voluntary
lead consumption of rats (37), enhanced the
effect of lead on blood pressure (38), and
reduced lead clearance (39).
In this case, the patient was started on a
high-calcium diet with these observations in
mind, with the appreciation that such a
change in diet had few risks, and after an
inability to control his blood pressure with
multidrug therapy. That his blood pressure
seemed to respond to a high-calcium diet
does not prove a causal relationship, and we
did not subsequently attempt to decrease his
dietary calcium to see if his blood pressure
would rise again; however, it raises several
interesting possibilities. Lead-induced hyper-
tension may be amenable to treatment with
dietary calcium, and blood pressure responses
to calcium supplementation observed in
some clinical trials (40) are experienced most
highly among individuals with elevated lead
burdens. It is possible, moreover, that hetero-
geneity of target-population lead burden is
partially responsible for the inconsistencies
seen in the calcium–blood pressure effect
across studies. 
These potential issues deserve further
study before a clear recommendation on cal-
cium supplementation can be made in
patients with chronic lead intoxication and
hypertension. In addition, it is important to
note that calcium supplementation in
patients with chronic renal failure, such as
this patient is beginning to have, carries a
heightened risk of soft tissue calcifications
including renal stone formation.
KXRF measurements of lead in bone.
The patient’s KXRF bone lead measurements
were taken as part of his participation in my
research. These measurements remain limited
to a handful of research centers performing
epidemiologic studies of chronic lead toxicity.
In clinical practice, KXRF measurements are
sometimes helpful in retrospective dose
assessment, for example, in determining
whether a patient with a missing or inade-
quate history of blood lead levels has a large
cumulative lead burden (versus on-going
environmental/occupational exposure) that is
responsible for a present elevation in blood
lead. KXRF-measured bone lead levels have
not yet been clearly shown to be a clinical
screening tool that produces results which
influence patient management, however.
Thus, although the correspondence of the
patient’s bone lead levels with overall research
ﬁndings is interesting, his bone lead levels are
not being used to target his treatment.
Other chronic lead exposure issues. In
addition to hypertension and renal insuffi-
ciency, chronic lead exposure is associated
with a number of other potential health
effects such as declines in neurocognitive
functioning (41) [as signified, for example,
by tests of manual dexterity, perceptual-
motor speed, and verbal recall (42–45)] and
general declines in mood [anger, confusion,
depression, fatigue, and tension (46)].
Peripheral nerve conduction velocity, pos-
tural balance, visual/auditory evoked poten-
tials, and cardiac conduction have also been
found to be reduced in studies of chronic
occupational lead exposure (47,48). 
In some studies, men with chronic lead
exposure were found to have an increased per-
centage of sperm with abnormal morphology
(49,50); decreased sperm concentration, total
sperm count, and total motile sperm count
(49,50); and alterations of male endocrine
function (51). Perhaps of most concern is the
potential threat posed by chronic lead expo-
sure to women during reproduction and
osteoporosis. Lead stored in bone, which has a
half-life of decades, is mobilized at a greatly
accelerated rate during pregnancy (52); more-
over, maternal bone stores of lead are associ-
ated with declines in infant birth weight and
weight gain velocity (53,54). Thus, chronic
lead exposure may pose a risk for women dur-
ing reproduction even if their lead exposure
ceased years ago. Heightened release of lead
from bone has also been associated with the
perimenopausal period and osteoporosis
(55,56). This may contribute to increased risk
of lead-associated toxicity such as hyperten-
sion and cognitive symptoms.
In the case presented, a brief mental 
status exam found no gross abnormalities of
cognitive function, and the patient did not
complain of disturbances of mood or repro-
duction. Detailed tests of subclinical func-
tion, however, were not available.
Prevention. This case clearly demonstrates
the importance of prevention of lead toxicity
through appropriate industrial hygiene and
work practices. In many industries, lead
exposure can be controlled by reengineering
the manufacturing process and adding
exhaust technologies that decrease overall lev-
els of lead contamination in workplace air and
on workplace surfaces. However, such
approaches are less feasible in construction,
and more reliance must be made on personal
protective devices. There is a hierarchy of
such devices, with the most protection from
purified air-powered respirators (Figure 2)
that provide clean air under positive pressure.
Negative pressure respirators and simple dust
masks provide protection that is substantially
less and, in many cases (such as sanding lead
paint), completely inadequate.
Individuals with lead exposure should also
receive regular medical screening. The OSHA
lead standard (7) requires that construction
workers exposed to lead (deﬁned as employees
exposed to lead above an “action” level of lead
in air of 30 µg/m3) be part of a program of
biological monitoring. Measurement of blood
lead levels is required, and measurement of
zinc protoporphyrin levels (which tend to rise
with 30 days of lead exposure) is advised every
2 months for the ﬁrst 6 months of exposure
and every 6 months thereafter. The frequency
is increased to every 2 months for employees
whose last blood lead level was ≥ 40 µg/dL. If
a blood lead level reaches 50 µg/dL and is
conﬁrmed by a second follow-up test within 2
weeks, an employee must be removed from
lead exposure until his/her blood lead declines
to ≤ 40 µg/dL. During removal from work,
an employer must maintain the worker’s full
earnings, seniority, and beneﬁts for up to 18
months. Annual medical examinations and
consultations must also be performed (57).
The standard also gives some latitude to phys-
icans to assess an individual’s ﬁtness for con-
tinued lead exposure irrespective of his/her
specific blood lead level, which may be
important in the case of a pregnant worker, in
view of recent research on the chronic toxicity
potential of lead at relatively modest levels of
exposure (53,54) and in view of the possible
enhanced vulnerabilities of individuals who
have preexisting disease.
Conclusions
Adult lead toxicity caused by occupational
and environmental construction activities
remains a relatively common condition
because of the wide prevalence of lead-based
paint in U.S. housing. Symptoms of acute
toxicity are often vague and demand a high
index of suspicion with a low threshold for
testing blood lead levels in order to make the
diagnosis. Among the possible sequelae of
chronic lead toxicity are hypertension,
chronic renal insufficiency, deficits of neu-
robehavioral function and mood, and repro-
ductive abnormalities. Some studies suggest
that these outcomes can occur with chronic
exposure, even when the levels of exposure fall
within the range allowed under current U.S.
and state regulations. In the case presented,
lead exposures clearly exceeded recommended
guidelines, and the patient had developed
hypertension that was relatively refractory to
multidrug therapy. Interestingly, the hyper-
tension seemed to respond to a high-calcium
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action, and the case suggests potential avenues
for future research. In the meantime, addi-
tional efforts should be made to educate
workers and homeowners regarding the haz-
ards associated with lead-based paint, and
individuals associated with such work should
be monitored carefully. 
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